Confirmed Control Announced Transaction verified BiopharmaceuticalsMigraine TherapeuticsNeurological Pharmaceuticals
Biohaven Pharmaceutical acquired by Pfizer
Pfizer agreed to acquire Biohaven Pharmaceutical, an US neurological pharmaceuticals brand on May 10, 2022. The transaction value is shown as USD 12bn. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Biohaven Pharmaceutical
- Acquirer
- Pfizer
- Seller
- -
- Announced
- 2022-05-10
- Geography
- United States
- Tags
- BiopharmaceuticalsMigraine TherapeuticsNeurological Pharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
Price / value
USD 12B
Consideration | USD
Basis: Public source
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
13.5x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 12bn consideration is treated as publicly disclosed or derived directly from public source data.
- EV / EBITDA is shown as 13.5x based on the available comp inputs.
- EBITDA and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- EBITDA basis was not stated in the source material.
Source summary
No public source summary has been published for this transaction yet.